IBM Generative AI Being Explored by Moderna for mRNA Vaccines

The News: IBM’s Generative AI and quantum computing technologies are being eyed by biotech company, Moderna, to see how these powerful new technologies can intensify the discovery and creation of the next generations of messenger RNA (mRNA) vaccines and medicines to battle human diseases. Moderna is one of the biotech companies, along with Pfizer and others, that used mRNA technology to quickly create vaccines in the global battle against Covid-19. Read the full Press Release on the IBM web site about Moderna’s recent plans to look at IBM technologies to help usher in new vaccines in the future.

IBM Generative AI Being Explored by Moderna for mRNA Vaccines

Analyst Take: IBM’s Generative AI and quantum computing technologies being harnessed by Moderna to increase the immense computing power needed for the discovery of new vaccines and medicines is a brilliant and timely move.

With the power and influence of Generative AI growing daily, combined with the still developing technology of quantum computing, Moderna is gaining two powerful tools that will certainly bring new innovations and speed to the complex and time-consuming processes of creating new medicines and vaccines.

Under an agreement between the two companies, Moderna and IBM researchers will use an AI foundation model called MoLFormer to help predict the properties of various molecules so that researchers can work to better understand the characteristics of potential mRNA medicines.

One of the detailed research areas being looked at is using the MoLFormer foundation model to optimize lipid nanoparticles, which surround and protect mRNA as it travels in the human body, and mRNA, which provides instructions for cells about how to fight diseases. These research efforts will help IBM and Moderna to combine their specialties in mRNA research and Generative AI to create new mRNA medicines that highlight safety and performance for patients.

In addition, IBM’s quantum computing expertise and experience will be utilized to assist Moderna researchers in experimenting with quantum technology to see how it could transform and solve scientific computing challenges that are virtually impossible using today’s classical computers.

To drive this work, Moderna will also be a part of the IBM Quantum Accelerator program and the IBM Quantum Network, which will give Moderna access to quantum computing systems and expertise as it looks at how these technologies can streamline and accelerate life sciences use-cases.

IBM Generative AI, Quantum and Vaccine Development

As the Covid-19 pandemic raged after beginning in early 2020, pharmaceutical companies and researchers immediately began deep research into finding vaccines and drugs that could help in getting the pandemic under control and saving lives around the world.

The use of mRNA as a starting point played a huge role in the process because it helped speed the delivery of experimental vaccines to save lives and get the pandemic under control.

The power of quantum computing here can also not be overstated. Quantum computing theoretically can pare down computations that would take thousands to millions of years to complete using classical computers into workable answers in hours, days, or weeks. This kind of power will make a huge difference in medicine once researchers learn how to best use the technology.

With this agreement between IBM and Moderna, medical research will gain even more power as these transformative technologies of Generative AI and quantum computing will be brought together to enable and grow broader discoveries and breakthroughs for medical science.

I believe that this mashup of these powerful technologies will bring immense new capabilities across the world of healthcare and will better prepare our fragile humanity for the next pandemics and serious global health catastrophes.

This is an important step, and one that I think will truly show the power of leading edge technologies and critical research being generated in a wide range of fields in health care. For everyone on Earth, this joint work by IBM and Moderna stands as a seminal moment in the fight against the diseases and pandemics of tomorrow.

Disclosure: The Futurum Group is a research and advisory firm that engages or has engaged in research, analysis, and advisory services with many technology companies, including those mentioned in this article. The author does not hold any equity positions with any company mentioned in this article.

Analysis and opinions expressed herein are specific to the analyst individually and data and other information that might have been provided for validation, not those of The Futurum Group as a whole.

Other insights from The Futurum Group:

IBM Launches Hybrid Cloud Mesh to Help Enterprises Regain Control

IBM Lakehouse as Part of watsonx.data for AI and Analytics

The Future of AI is Hybrid: Look No Further than Your Devices to Scale Generative AI

Related Insights
Kore.ai and Atos Bet on Sovereign Agentic AI, Will UK Enterprises Demand Proof, Not Promises?
July 8, 2026

Kore.ai and Atos Bet on Sovereign Agentic AI, Will UK Enterprises Demand Proof, Not Promises?

Kore.ai and Atos announce a strategic partnership to deliver Sovereign AI solutions to UK organizations, addressing data residency and compliance requirements in the rapidly expanding $181B AI platforms market....
Provisioned Throughput Redefines Open Model Inference Economics and Predictability
July 8, 2026

Provisioned Throughput Redefines Open Model Inference Economics and Predictability

Together AI's Provisioned Throughput offers enterprises reserved inference capacity, token-based pricing, 99% uptime SLA, and up to 90% cost savings, addressing critical production AI concerns....
Will Apple’s New Siri AI Deliver on the Promise of Apple Intelligence?
July 7, 2026

Will Apple’s New Siri AI Deliver on the Promise of Apple Intelligence?

Olivier Blanchard, Research Director at The Futurum Group, examines how Siri AI transforms Apple Intelligence from a feature set into a systemwide layer for apps, workflows, and user experiences across...
Can ASUS Bring Data-Center-Class AI Infrastructure to the Deskside
July 7, 2026

Can ASUS Bring Data-Center-Class AI Infrastructure to the Deskside?

Olivier Blanchard, Research Director at The Futurum Group, examines how ASUS is bringing data-center-class AI infrastructure to the deskside with the ExpertCenter Pro ET900N G3 and what its local AI...
How NVIDIA is Building a Critical Safety Layer for Physical AI
July 7, 2026

How NVIDIA is Building a Critical Safety Layer for Physical AI

Olivier Blanchard, Research Director at The Futurum Group, examines NVIDIA Halos for Robotics and whether a unified safety architecture could become a foundational requirement for scaling physical AI in industrial...
Does Qodo's Codebase-Wide Enforcement Redefine What 'AI Code Review' Means?
July 7, 2026

Does Qodo’s Codebase-Wide Enforcement Redefine What ‘AI Code Review’ Means?

Qodo's full codebase context approach positions it as a pre-merge quality gate, addressing enterprise reliability concerns that have slowed AI adoption in software engineering workflows....

Book a Demo

Welcome

The vision behind everything in Futurum’s Custom Research practice is this: research should show you what is happening, what comes next, and what to do about it. It should be personal to each audience, easy for people to grasp, and structured so LLMs can reason over it accurately. And it should be fast and turnkey; you want answers now, not another project to carry for quarters.

Whether you are defining business, channel, or go-to-market strategy; evaluating vendors or justifying ROI; or commissioning research to fill an emerging market need, we have your back, with a program that answers your questions with the objectivity and credibility to drive real decisions.

To do it, we bring unmatched data to bear: Futurum research, surveys, and market projections; validated market feeds; ETR’s 15 years of insight from 10,000 technology decision-makers; G2’s buyer and user data; and what our analysts hear every day. Add leading primary collection, from AI-moderated voice interviews to surveys and analyst-led interviews, all turnkey, and every project comes out credible, nuanced, and actionable.

And we don’t just drop the results in your lap. For internal work, we provide analyst-led sessions, interactive dashboards, and a range of formats. For market-facing work, Futurum delivers turnkey activation and amplification that actually gets seen, by people and by LLMs, through our media and share of voice. This is research that moves decisions and markets.

We will meet you wherever you are, from a fast-turn brief to a multi-year program, and shape the work to your goals, timeline, and budget. The right program for your moment.

If any of this is useful, I would love to talk.

Benjamin Brown, VP Custom Research, Futurum Research

Benjamin Brown

VP, Custom Research · The Futurum Group

Newsletter Sign-up Form

Get important insights straight to your inbox, receive first looks at eBooks, exclusive event invitations, custom content, and more. We promise not to spam you or sell your name to anyone. You can always unsubscribe at any time.

All fields are required






Thank you, we received your request, a member of our team will be in contact with you.